GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2023 Report. Evidence-based strategy document for COPD diagnosis, management, and prevention, with citations from the scientific literature. View 2023 Executive Summaries, including a podcast discussion between Dr. Alvar Agusti and ERJ regarding the new changes

Family physicians are key players in managing COPD through diagnosis, treatment, and coordination of care. At this time, screening is not recommended by the USPSTF for COPD in asymptomatic...

This guideline has outlined follow-up recommendations for the first 1-4 weeks and 12-16 weeks of hospital discharge in COPD patients with spirometry (Tables 3 and 4). Overall, the follow-up instructions should help reduce re-hospitalization and provide a better transition of care.

Chronic obstructive pulmonary disease (COPD) is suspected in patients with a history of smoking, occupational and environmental risk factors, or a personal or family history of chronic lung disease. Presents with shortness of breath, wheeze, …

6 天之前 · Management of stable COPD. The vaccination scheme for COPD patients is updated in the GOLD 2025 document to reflect the guidance of the US Centers for Disease Control (CDC), including yearly influenza, updated SARS-CoV-2, pneumococcal conjugate vaccines (single dose of PCV20 or PCV21), respiratory syncytial virus (RSV) for patients ≥60 years or with …

2024年5月26日 · Chronic obstructive pulmonary disease (COPD) was redefined in the 2023 GOLD guidelines as “a heterogenous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often ...

Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation from airway or alveolar abnormalities. The goal of medical treatment...

guideline on diagnosis and management of stable chronic obstructive pulmonary disease (COPD) and is intended for clinicians who manage patients with COPD. This guideline addresses the value of history and physical examination for predicting airflow obstruction; the value of spirometry for screening or diagnosis of COPD; and COPD manage-

In patients with chronic obstructive pulmonary disease (COPD) who complain of dyspnea or exercise intolerance, we recommend long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy (strong recommendation, moderate certainty evidence).

The objective of this guideline is to improve the quality of care for patients with COPD by providing a framework for management and treatment of mild to moderate acute exacerbations, and to improve symptoms, quality of life, and lung function while reducing morbidity and mortality.